Finkelstein Thompson LLP Announces Investigation Of SenoRx Inc.

Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of SenoRx Inc. (“SenoRx” or the “Company”) (Nasdaq: SENO) arising from the Company’s announcement of its intent to merge with C. R. Bard Inc. (“C. R. Bard”). Under the terms of the agreement, SenoRx shareholders will receive $11.00 in cash for every share of SenoRx stock they own in a transaction valued at approximately $200 million.

The investigation is focused on the potential unfairness of the consideration to SenoRx’s shareholders and the process by which SenoRx’s Board of Directors considered and approved the transaction. C. R. Bard is only offering a 13.6% premium over the closing price of SenoRx the day before the announcement.

If you are interested in discussing your rights as a SenoRx shareholder, or have information relating to this investigation, please contact Finkelstein Thompson's Washington, DC offices at [phone] or by email at [e-mail].

Finkelstein Thompson LLP has spent over three decades delivering outstanding representation to institutional and individual clients in financial litigation, and has been appointed as lead or co-lead counsel in dozens of shareholder class actions. Indeed, the firm has served in leadership roles in cases that have recovered over $1 billion for investors and consumers.

To learn more about Finkelstein Thompson LLP, please visit our web site at www.finkelsteinthompson.com. Attorney advertising. Prior results do not guarantee similar outcomes.

>To order reprints of this article, click here: Reprints